CD68 and Hodgkins lymphoma: We report that the number of CD68+ tumor‐infiltrating macrophages and presence of B‐symptoms are prognostic markers in ABVD‐treated HL also in the era of interim PET, while changes in TARC levels do not add prognostic information.